Physician profile
Michael D Bennett
NPI 1043274111
$107,738.63
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $53K · 2021: $2,928 · 2022: $4,696.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $96,154.64 | 2019-2020 | |
| US Retina LLC | $10,922.57 | 2019-2022 | |
| Lensar, INC. | $375.72 | 2019 | |
| Allergan, INC. | $198.13 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $32.34 | 2019 | |
| Carl Zeiss Meditec, INC. | $19.15 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $18.61 | 2019 | |
| Genentech USA, INC. | $17.47 | 2022 |
Research and ownership
$228,419.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.